RealRate

PHARMACEUTICAL 2017

CATALYST PHARMACEUTICALS INC. Rank 135 of 313



Selling, Cost of Goods Research and General and Other Expenses Sold Administrative Development 60.8%8.56% Expense -44.1% -73.9% 8.56% 60.8% -44.1% -73.9% Other Net Intangible Property and Assets. Expenses Revenues Other Assets Income Equipment Current Assets -48.6% -65.9% -15.2% 10.3% -8.41% 411% -19.8% -48.6% 10.3% -65.9% 411% -19.8% -15.2% -8.41% Liabilities Net Income Assets -104% 11.9% 246% 36.7% 89.7% -104% Stockholders Comprehensive Net Income -19.5% Equity 94.1% -104% 126% -104% 126% Economic Capital Ratio 280%



PHARMACEUTICAL 2017

CATALYST PHARMACEUTICALS INC.



Rank 135 of 313

The relative strengths and weaknesses of CATALYST PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CATALYST PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 411% points. The greatest weakness of CATALYST PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is -137%, being 280% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	41,454
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,095
Liabilities, Non-Current	0
Other Assets	8.9
Other Compr. Net Income	0
Other Expenses	-886
Other Liabilities	303
Other Net Income	322
Property and Equipment	244
Research and Development	11,370
Revenues	0
Selling, General and Administrative Expense	7,910

Output Variable	Value in 1000 USD
Assets	41,707
Liabilities	2,398
Expenses	18,394
Stockholders Equity	39,309
Net Income	-18,072
Comprehensive Net Income	-18,072
Economic Capital Ratio	-137%